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Abstract
Abstract This study shows that melanoma-associated fibroblasts (MAFs) suppress cytotoxic T lymphocyte (CTL) activity and 
reveals a pivotal role played by arginase in this phenomenon. MAFs and normal dermal fibroblasts (DFs) were isolated from 
surgically resected melanomas and identified as Melan-A-/gp100-/FAP+ cells. CTLs of healthy blood donors were activated 
in the presence of MAF- and DF-conditioned media (CM). Markers of successful CTL activation, cytotoxic degranulation, 
killing activity and immune checkpoint regulation were evaluated by flow cytometry, ELISPOT, and redirected killing assays. 
Soluble mediators responsible for MAF-mediated effects were identified by ELISA, flow cytometry, inhibitor assays, and 
knock-in experiments. In the presence of MAF-CM, activated/non-naïve CTLs displayed dysregulated ERK1/2 and NF-κB 
signaling, impeded CD69 and granzyme B production, impaired killing activity, and upregulated expression of the nega-
tive immune checkpoint receptors TIGIT and BTLA. Compared to DFs, MAFs displayed increased amounts of VISTA and 
HVEM, a known ligand of BTLA on T cells, increased l-arginase activity and CXCL12 release. Transgenic arginase over-
expression further increased, while selective arginase inhibition neutralized MAF-induced TIGIT and BTLA expression on 
CTLs. Our data indicate that MAF interfere with intracellular CTL signaling via soluble mediators leading to CTL anergy 
and modify immune checkpoint receptor availability via l-arginine depletion.
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Abbreviations
BEC  (S-(2-Boronoethyl)-l-cysteine) hydrochloride
BM  Basal medium
BTLA  B and T lymphocyte associated
CAF  Cancer-associated fibroblasts
CM  Conditioned media
CTL  Cytotoxic T lymphocyte
DF  Normal dermal fibroblasts
DiD  (1,1′-Dioctadecyl-3,3,3′,3′-
tetramethylindodicarbocyanine, 4-chlorobenze-
nesulfonate Salt)
DiL  (1,1′-Dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate)
FAP  Fibroblast-activation protein
GzmB  Granzyme B
HVEM  Herpesvirus entry mediator
ICR  Immune checkpoint receptors
IDO  Indoleamine-2,3-dioxygenase
IFNγ  Interferon gamma
LAG-3  Lymphocyte-activation gene 3
MAF  Melanoma-associated fibroblasts
NO  Nitric oxide
NOS  Nitric oxide synthase
PD-1  Programmed cell death protein 1
PD-L1  Programmed death-ligand 1
PGE2  Prostaglandin E2
Runx3  Runt-related transcription factor 3
TGFβ  Transforming growth factor beta
TIGIT  T cell Immunoreceptor with Ig and ITIM 
Domains
TIM-3  T cell immunoglobulin and mucin-domain 
containing-3
TNFα  Tumor necrosis factor alpha
VEGF  Vascular endothelial growth factor
VISTA  V-domain Ig suppressor of T cell activation
Introduction
Cancer-associated fibroblasts (CAF) represent a heteroge-
neous cell population, considered to originate from various 
possible precursors, such as resting resident fibroblasts, bone 
marrow-derived mesenchymal stem cells, hematopoietic 
stem cells, endothelial cells, local epithelial cells, or adi-
pocytes [1]. CAFs contribute actively to tumor progression 
by promoting matrix remodeling, invasion and neovascu-
larization. CAFs are also known to suppress local immune 
responses via a wide array of cytokines, small molecular 
mediators and metabolic enzymes, such as transforming 
growth factor beta (TGFβ), IL-6, prostaglandin E2 (PGE2), 
VEGF and indoleamine-2,3-dioxygenase (IDO)/kynurenine 
[2, 3]. The relevance of CAFs in local immunosuppression 
is underlined by multiple observations showing that their 
removal may prolong survival or achieve immune-mediated 
rejection of established tumors [4–7].
CAFs can be found in virtually all solid tumors; in some, 
they are highly abundant (e.g., ovarian cancer); while in oth-
ers, they are less frequent (e.g., melanoma). In melanoma, 
it is well documented that CAF (melanoma-associated 
fibroblasts, MAF) are rather capable suppressors of NK-
cell activity via multiple ways, including PGE2-dependent 
suppression [8–10], and this phenomenon is probably not 
restricted to melanoma [11, 12].
Interestingly, it has been shown that activated effector 
CD8+ T cells express the same prostaglandin receptors that 
were reported to be involved in MAF-mediated NK-cell 
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suppression. Also, CD8+ T cells exhibit decreased interferon 
gamma (IFNγ), tumor necrosis factor alpha (TNFα) and IL-2 
production and impaired survival upon exposure to PGE2 
[13]. However, it has not yet been analyzed whether MAF 
could influence CD8+ CTL responses via PGE2, via the 
release of immunosuppressive cytokines, metabolic repro-
gramming, immune checkpoint modulation, or other ways 
of immunosuppression. Considering that (i) CD8+ T cells 
play a pivotal role in melanoma rejection, (ii) state-of-the art 
melanoma therapies may achieve partial to complete patient 
responses by mobilizing CTLs, and (iii) factors contributing 
to therapy failure remain elusive, in this study, we sought to 
analyze possible parallels between MAF action on NK cells 
and CTLs, focusing on the latter.
Materials and methods
Patients and samples
Skin biopsies of thirteen melanoma patients were collected 
for research purposes following IRB (Institutional Review 
Board)-approved protocols, after obtaining informed con-
sent, at the Department of Dermatology, Venereology and 
Dermatooncology, Semmelweis University, Budapest, Hun-
gary. The study was conducted according to the Declara-
tion of Helsinki principles and approved by the Hungarian 
Scientific and Research Ethics Committee of the Medical 
Research Council (ETT TUKEB; Decree No. 32/2007, sup-
plements 32-2/2007 and 32-3/2007).
Fibroblasts
Melanoma-associated fibroblasts (MAFs) were isolated from 
either primary or metastatic tumors of melanoma patients. 
The inner tumor mass was minced into ~ 1 mm3 pieces and 
digested in 20 ml DMEM supplemented with 200 U/ml type 
IV collagenase and 0.6 U/ml dispase (Thermo Scientific, 
17104019, 17105041) as described elsewhere [14, 15]. 
MAFs were separated from melanoma cells by differential 
adhesion and their purity was assessed by flow cytometry. 
Normal dermal fibroblasts (DFs), serving as controls, were 
derived from non-tumorous intact edges (tissue > 1 cm from 
the tumor edge) using the same approach. Isolation of both 
MAFs and DFs from the same patient was successful in nine 
cases. These autologous, matched pairs of primary cells (see 
Supplementary table 1) were used in all subsequent analyses. 
Cells were used at five or fewer passages and maintained 
in standard DMEM (Gibco, 31885-023) supplemented with 
20% FBS (Gibco, 10437-036), 1% penicillin–streptomycin 
(P/S) and 1% l-glutamine (Sigma-Aldrich, P4333, 59202C).
Preparation of DF‑ and MAF‑conditioned media
Viable isolated DF and MAF cultures reaching 75–80% 
confluence were washed twice in 1 × PBS, and further cul-
tivated in 10-ml basal medium (BM) consisting of DMEM, 
1% P/S, 1% l-glutamine and 0.5% BSA (Miltenyi Biotec, 
130-091-376) for 48 h to prepare conditioned media (CM). 
In some experiments, BM were supplemented with 500-μM 
BEC (S-(2-boronoethyl)-l-cysteine) hydrochloride (Sigma-
Aldrich, SML1384) to suppress arginase 1 and 2 activity. 
Finally, conditioned medium samples were centrifuged at 
4000×g for 10 min, filtered through a 0.45-μm strainer, ali-
quoted and stored at − 80 °C until further use.
MAF transfection
One million MAF cells were transfected with 1 ug of pEZ-
M73 plasmid DNA containing the full-length human argin-
ase-2 ORF under the control of a CMV promoter (Tebu-Bio 
EX-M0204-M73). Transfection was done by electroporation 
using a P2 Primary Cell 4D-Nucleofector™ X Kit (Lonza 
V4XP-2024) and a 4D Nucleofector (Lonza). Successful 
transfection was confirmed by Q-PCR. Conditioned media 
were prepared and applied as above.
Cultivation of CD8+ T cells in DF‑ 
and MAF‑conditioned media
Whole blood samples were collected from healthy volun-
teers (see Supplementary Table 2) by venipuncture in ACD 
A tubes (Greiner Bio-One, 455055). PBMC were isolated 
over Ficoll–Histopaque (Sigma, 10771). Separation of 
untouched human CD8+ T cells was carried out by nega-
tive magnetic selection using the Human CD8+ T Cell Isola-
tion Kit (Miltenyi, 130-096-495) and an AutoMACS Pro II 
automated cell sorter (Miltenyi). T cells were counted and 
seeded on 48-well non-treated culture plates at a density 
of 1 × 106 cells/well, in a 1:1 mixture of 250 ul of MAF- 
or DF-derived CM, and 250 ul X-vivo 15 medium (Lonza, 
04-418Q) supplemented with 1% P/S, glutamine and 5% 
normal human male AB serum (Sigma-Aldrich, H4522).
Activation of CD8+ T cells in DF‑ 
and MAF‑conditioned media for downstream 
analyses
Unless otherwise stated, T cells were incubated in CM for 
24 h before activation. Subsequently, T cells were distributed 
into 96-well round-bottom plates that were previously coated 
with 5 ug/ml anti-human CD3 (UCHT1; BD Biosciences, 
555329) without changing the culture media. Next, 5 ug/ml 
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anti-human CD28 (CD28.2; BD Biosciences, 555728) was 
added and cells were maintained for 48 h before downstream 
analyses were performed.
Flow cytometry
Cells were stained with primary and secondary antibodies 
in pre-determined dilutions at 4 °C for 15 min (see Supple-
mentary Table 3). Intracellular antigens were stained after 
cell surface antigens, using Sony’s Fixation and Intracel-
lular Staining Permeabilization Wash Buffers for cytoplas-
mic, (Sony, 2704005, 2705010), and eBioscience’s Foxp3/
Transcription Factor Staining Buffer Set for nuclear proteins 
(Thermo, 00-5523-00). Cytokines and secretory molecules 
were analyzed after Brefeldin A treatment (eBioscience, 
00-4506-51); 5 µg/ml for 2 h at 37 °C before staining. Intra-
cellular nitric oxide (NO) levels were determined using 
DAF-FM staining (Thermo Fisher, D23844), as recom-
mended by the manufacturer.
Signaling assays
MACS-sorted CD8+ T cells were cultivated in the pres-
ence of DF- and MAF-CM as above. Subsequently, T cells 
were exposed to a-CD3 (HIT3a) and a-CD28 (CD28.2) for 
30 min, on wet ice, in the original cell culture media, and 
then washed twice with ice-cold PBS and finally activated 
by adding AffiniPure F(abʹ)2 Fragment Goat Anti-Mouse 
IgG, F(ab’)2 fragment-specific crosslinker antibody (Jack-
son ImmunoResearch, 115–006-006) in DMEM at 37 °C for 
10 min. Cells were washed with ice-cold 1 × PBS, fixed and 
stained for flow cytometry, as above. In other experiments, 
cells were lysed and analyzed by a Proteome Profiler Human 
Phospho-Kinase Array Kit (R&D, ARY003B), as per the 
manufacturer’s instructions. Specific signals were detected 
by a ChemiDoc XRS + system (Bio-Rad), and normalized 
to Hsp60 as internal reference.
Redirected killing assay
Redirected killing assays were performed on MACS-sorted 
CD8+ T cells exposed to DF-, or MAF-conditioned media 
for 24 h in the presence or absence of anti-CD3/28 [16, 
17]. P815 mouse mastocytoma cells, used as targets, were 
maintained in standard DMEM, 10% FBS, 1% P/S and 
l-glutamine. For redirected killing assays, equal amounts 
of P815 cells (1 × 106/ml/assay) were stained with DiD 
(1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine, 
4-chlorobenzenesulfonate salt) and DiL (1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindocarbocyanine perchlorate) dyes, 
respectively (Thermo Fisher, V22887, V22885). After exten-
sive washing, DiD-stained cells, serving as specific targets, 
were loaded with mouse anti-human CD3 (eBioscience, 
555336) and mouse anti-human CD28 (BD Biosciences, 
555728) antibodies capable of activating CD8+ T cells. DiL-
stained cells, serving as non-specific target controls were left 
unloaded. Target and non-target P815 cells were mixed at a 
ratio of 1:1 and co-cultured with CD8+ T cells at a ratio of 
10:1 on 96-well U-bottom plates for 5 h. Subsequently, cul-
tures were stained with Annexin V FITC (Biotium, 29005), 
and specific and unspecific killing was assessed by flow 
cytometry, based on annexin V staining of DiD- and DiL-
labeled P815 cells, respectively. Percent specific lysis was 
calculated, as follows: 100 × (lysis of specific targets − lysis 
of non-specific target controls)/(100 – lysis of non-specific 
target controls).
ELISA
Levels of TGFβ-1, IL-6, Prostaglandin E2, l-kynurenine, 
and SDF-1/CXCL12 in MAF and DF supernatants were 
comparatively analyzed by dedicated ELISA assays fol-
lowing the manufacturers’ instructions (see detailed assay 
information in Supplementary Table 3).
ELISPOT
IFN-γ and granzyme B release was measured with the 
Human IFN-γ/Granzyme B Dual-Color ELISpot Kit (see 
detailed assay information in Supplementary Table  3). 
CD8+ T cells were isolated as described previously, and 
incubated in MAF- or DF-derived CM for 24 h. Next day, 
1 × 105 primed T cells were placed in each well of the ELIS-
POT plate in duplicates. Cells were activated with 5 ug/ml 
anti-human CD3 (HIT3a) and anti-human CD28 (CD28.2) 
for 48 h, or left untreated. Results were evaluated accord-
ing to the manufacturer’s instructions, using an Alpha CTL 
Immunoscan ELISPOT reader.
Q‑PCR
Total RNA was isolated from fibroblasts using miRNeasy 
Kit (Qiagen 217004). Five hundred-ng RNA was reverse 
transcribed with a High-Capacity RNA-to-cDNA Kit 
(Thermo 4387406). A human Arginase-2 Taqman probe set 
(Thermo 4331182) was used to perform RT-Q-PCR on a 
7900HT Sequence Detection System (Thermo).
MAF arginase activity assay
Evaluation of arginase activity was carried out using a col-
orimetric Arginase Activity Assay Kit (Sigma-Aldrich, 
MAK112) following the manufacturer’s instructions. Results 
were evaluated according to the manufacturer’s instructions 
and normalized to total protein content.
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Statistical analysis
All statistical analyses were carried out with Graphpad 
Prism v7.00. Normality and equal variance were checked 
using Shapiro–Wilk tests and F tests, respectively. Nor-
mally distributed data with equal variance were analyzed 
using paired Student’s t tests, ratio paired T tests, unpaired 
t tests, one-way or two-way repeated measures ANOVA. 
All other datasets were compared using Mann–Whitney 
rank-sum tests, Wilcoxon matched-pairs rank-sum tests, or 
Friedman’s test, as appropriate. Differences were considered 
significant if p < 0.05. Sample sizes (n) indicated in figure 
legends refer to the actual number of independent mela-
noma patients (MAF, DF) and blood donors (CD8+ T cells) 
recruited in the experiment. Unless otherwise indicated (see 
Fig. 7), no MAF cultures, DF cultures, conditioned media or 
CD8+ T cell isolates were re-used in multiple experiments 
summarized in the same figure panel. In paired experimental 
designs and repeated measures studies, the same fibroblast 
culture or T cell isolate received multiple different treat-
ments, or their combinations.
Results
Isolation and characterization of MAFs
Fibroblasts were isolated from cutaneous melanomas 
(MAFs) or from the healthy distal edges of the same surgi-
cal specimen, following elliptical excision (DFs, see Sup-
plementary Table 1). Next, primary cultures of bona fide 
fibroblasts were extensively characterized by flow cytometry 
to validate their identity and exclude samples contaminated 
by melanoma cells. A three-marker panel was used, targeting 
melanoma-specific (melanA and gp100) and CAF markers 
(fibroblast-activation protein or FAP) (Fig. 1). MAF cul-
tures displaying > 3–4% melanA or gp100 positivity were 
excluded from further experiments (Fig. 1, marked with 
asterisks); two such cultures were found out of sixteen.
Early events of CD8+ T cell activation are 
compromised by MAF supernatants
We first tested whether early steps of CD8+ T cell activa-
tion were affected by the presence of MAF-released soluble 
factors. To this end, we examined whether MAF-CM would 
affect expression of either CD69, an early T cell activation 
marker, or that of CD107a (LAMP-1), a marker of cyto-
toxic degranulation. We found that CD8+ T cells activated 
by anti-CD3/28 in the presence of MAF-CM displayed less 
CD69 compared to CD8+ T cells activated in the presence 
of DF-CM, as the frequency of CD69+ cells was decreased. 
Similarly, the ratio of CD69(+) vs. CD69(−) cells decreased 
significantly in the MAF-CM vs DF-CM group (Fig. 2a). 
No significant difference was found in the amounts of cell 
surface CD107a, however (not shown).
Selective impairment of CD8+ T cell effector 
molecule production and release by MAF 
supernatants
Next, we investigated if MAF-derived soluble factors could 
modulate expression of cytotoxic T cell effector molecules 
or killing activity. We tested the activation-induced produc-
tion of IFN-γ and granzyme B (gzmB) by intracellular flow 
cytometry. There was no significant difference between 
MAF- and DF-instructed CD8+ T cells in terms of IFN-γ 
production (not shown). However, intracellular gzmB lev-
els were significantly reduced in the presence of the MAF 
CM in CD8+ T cells compared to DF CM-treated cells. 
Similar to CD69, both gzmB production and the frequency 
of gzmB-positive cells (Fig. 2b) were reduced. Impact of 
MAF-CM on CTLs’ gzmB production was comparable to 
that of in vitro exposition to TGF-β in the dose range stud-
ied, and this held true regardless of the presence or absence 
of fibroblast-conditioned media (see Supplementary Fig. 1). 
Subsequent analysis of the release of gzmB and IFN-γ from 
MAF-exposed CTLs by ELISPOT corroborated these find-
ings. ELISPOT confirmed that both the number of aCD3/28-
activated gzmB-secreting CD8+ T cells, and the amount of 
Fig. 1  Flow cytometric characterization of primary fibroblast cultures 
obtained from resected melanoma samples. a Representative flow 
cytometry plots showing typical staining of validated, melanoma-
free MAF cultures and Malme 3M melanoma cells used as refer-
ence. Specific staining with FAP-, GP100- and Melan-A antibodies 
is shown compared to isotype control (IC). b A heat plot summarizes 
expression patterns of all three markers, as observed on isolated MAF 
(n = 19) and DF samples (n = 11). Two primary MAF cultures out of 
fifteen, indicated by stars, were identified as melanoma-contaminated 
and censored. Summarized data from six independent measurements
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gzmB released by them were reduced by pre-incubaton with 
MAF-CM (Fig. 2c). However, in line with flow data, IFN-γ 
release was not affected by MAFs (not shown).
MAF‑derived soluble factors hamper CD8+ T 
cell‑mediated killing
As gzmB production and release correlate with cytotoxic T 
cell killing capacity, in vitro cytotoxic effector functions of 
activated CD8+ T cells were also analyzed in the presence 
of MAF-CM. Standard redirected killing assays [18–22] 
were performed using P815 cells serving as targets, either 
preloaded with anti-CD3/28 antibodies and labeled with 
DiD (targets to assess specific killing) or left untreated and 
labeled with DiL (to assess aspecific killing of bystander 
non-target cells). We observed that the MAF CM-treated 
CD8+ T cell group induced significantly less cell death than 
the DF CM-treated group (Fig. 2d), which is in line with the 
observed attenuation of gzmB production.
MAFs interfere with T cell signaling
Considering that impaired T cell function may be caused 
by lack of proper co-stimulation or other forms of aberrant 
signal transduction, we next analyzed if MAF supernatants 
influenced T cell signaling, required for full T cell activation 
and differentiation. In pilot studies, we interrogated early 
(CD3ζ-chain activation, Tyr142-P), and downstream of T 
cell signaling events (NF-κB activation, Ser536-P) as well 
as a key transcription factor associated with late CD8+ T 
cell differentiation (Runt-related transcription factor 3 or 
Runx3). MAFs suppressed NF-κB phosphorylation, while 
CD3ζ and Runx3 remained unaffected (Fig. 3a–c). Based 
on this observation, we next utilized phospho-kinase protein 
arrays to gain further insight into aberrant T cell signal-
ing downstream of TCR. Although the majority of TCR-
related kinase pathways remained functional, suppression 
of NF-κB activation was accompanied by increased ERK1/2 
phosphorylation in MAF-exposed CD8+ T cells (Fig. 3D). 
Taken together, these data suggest that there is an imbal-
ance between aCD3-mediated TCR signaling and aCD28-
provided co-stimulation in MAF CM-exposed T cells.
MAF supernatants modify immune checkpoint 
receptor expression of CD8+ T cells
Immune checkpoint receptors (ICR) are known to regulate 
CD8+ T cell activity during anti-tumor immune responses. 
Therefore, we wanted to explore if MAFs can influence the 
synthesis of select ICRs in CD8+ T cells. Expression pat-
terns of PD-1 (programmed cell death protein 1), TIM-3 
(T cell immunoglobulin and mucin-domain containing-3), 
LAG-3 (lymphocyte-activation gene 3), TIGIT (T cell 
Fig. 2  MAF-CM interferes with CD8+ T cell activation, intracellular gran-
zyme B production, granzyme B release, and ex vivo killing. a Expression of 
CD69 was examined upon exposition of healthy blood donors’ CD8+ T cells 
to MAF- or DF-derived conditioned media and their subsequent activation by 
anti-CD3/CD28. Comparative analysis of mean fluorescence intensities (MFI) 
by ratio paired t test (p = 0.0053; n = 6), and percentage of CD69 positive cells 
analyzed by paired t test (p = 0.0058; n = 6) (result of two independent experi-
ments) and representative staining. b Representative flow cytometry data 
displaying intracellular (IC) gzmB staining of split CD8+ T cell cultures acti-
vated by aCD3/28 after exposition to MAF-CM or DF-CM. Pairwise analysis 
of mean fluorescence intensity and percent positive cells are shown (paired t 
test p = 0.0346, p = 0.0327, n = 6 respectively; three independent experiments). 
c Comparative analysis of gzmB release (spot area) and gzmB-releasing cell 
numbers (spot number) in control and aCD3/28-treated CTLs after exposi-
tion to MAF-CM and DF-CM using ELISPOT assays (two-way RM ANOVA, 
p = 0.0409, p = 0.0050, respectively, n = 7, one experiment). d Redirected kill-
ing assay using P815 cells pre-stained with DID and pre-loaded with aCD3/28 
(specific lysis targets) and their DIL-stained but otherwise untreated coun-
terparts (non-specific lysis controls). Lysed P815 cells were identified using 
annexin V-staining and data were analyzed by ratio paired t test (p = 0.0223, 
n = 5) (two independent experiments). Representative staining and data evalu-
ation are shown
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immunoreceptor with Ig and ITIM domains) and BTLA (B 
and T lymphocyte attenuator) were analyzed after treatment 
with MAF and DF-CMs. We found an increased expres-
sion of TIGIT and BTLA in CD45RO+ non-naïve/memory 
cytotoxic T cells following exposition to MAF-CM as com-
pared to DF-CM (Fig. 4). The expression of PD-1, TIM-3, 
or LAG-3 on CD8+ T remained unaffected by MAF-CM 
compared to DF-CM, regardless of aCD3/28 activation or 
naïve/memory status (not shown).
MAFs exhibit a skewed spectrum of immune 
checkpoint regulators
The expression of CAF-ICR ligands and the possible role of 
these molecules in CAF-mediated immunomodulation have 
been controversial. To analyze the question whether MAF 
could affect T cell ICR signaling, cell surface expression of 
several ICR ligands was compared betweenMAFs and DFs. 
Fig. 3  MAF-CM modulates CTL phosphorylation cascades down-
stream of TCR. a Analysis of CD3ζ-chain activation (n = 9). b NF-κB 
activation (n = 9) and c Runx3 levels (n = 5) in unstimulated, and 
DF-CM- or MAF-CM-exposed CD8+ T cells upon activation by 
aCD3/28. CD3ζ-chain and NF-κB phosphorylation were assessed 
10  min post activation; Runx3 levels 48  h post activation. Repre-
sentative data are shown to the right (Ratio paired t test p = 0.0093 
for NF-κB; results from two independent experiments). d Screening 
analysis of 43 additional phosphorylated kinases in DF- and MAF-
CM-treated CD8+ T cells using a phosphokinase array (n = 4). Shown 
are phosphorylation patterns of thirteen typical CD8+ T cell signaling 
proteins detected by the array 10 min post T cell activation (bottom). 
ERK1/2 phosphorylation data are shown magnified (top left, paired 
t test p = 0.0147). Representative 3D densitometry data display dif-
ferences in ERK1/2 activation are shown (top right). Each phospho-
rylated protein is represented by a pair of spikes; volume of spikes 
equals to intensity of protein phosphorylation. Results obtained from 
one experiment
Fig. 4  MAF-CM-treated activated non-naïve CD8+ T cells increase 
BTLA and TIGIT checkpoint receptor expression. BTLA and TIGIT 
expression on activated non-naïve/memory CD45RO+ CD8+ T 
cells upon exposition to DF- and MAF-conditioned media; paired t 
test (BTLA: p = 0.0353 and TIGIT: p = 0.0050, n = 6, data from one 
experiment
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We tested the presence and expression of Herpesvirus entry 
mediator (HVEM), Galectin-3, Galectin-9, Programmed 
death-ligand 1 (PD-L1), CD155 (poliovirus receptor) and 
V-domain Ig suppressor of T cell activation (VISTA). We 
found that compared to DFs, MAFs displayed increased 
amounts of the negative CTL regulators VISTA and HVEM 
(Fig. 5).
MAFs display increased l‑arginase activity 
and secrete elevated levels of CXCL12
We next sought to explore the molecular pathways 
involved in MAF CD8+ T cell interactions. Candidate 
molecules were selected based on previous reports and 
included immunomodulatory factors synthetized by CAFs. 
Secreted TGF-β [23], IL-6, CXCL12 [5] and PGE2 [8] 
were analyzed by ELISA in MAF-CM and DF-CM. l-argi-
nine catabolism by intracellular l-arginase [24] was ana-
lyzed in cell lysates using a dedicated l-arginase activity 
assay. l-tryptophan catabolism by Indolamine-2,3-dioxy-
genase [25] was assessed by measuring kynurenine in the 
CM. l-arginase activity was detected in both MAF and DF 
and it was highly elevated in MAF compared to DF cells 
(Fig. 6A). To corroborate this finding, we next analyzed 
NO production by intracellular DAF-FM staining in a sim-
ilar manner, comparing MAF and DF cells. l-arginase and 
nitric oxide synthase (NOS) are in active competition for 
free l-arginine as their common substrate, and increased 
arginase activity was repeatedly shown to induce uncou-
pling of NOS resulting in decreased NO production [26]. 
Indeed, we found that MAF produced markedly less NO 
than DF (Fig. 6b), suggesting that l-arginase upregula-
tion and consequent l-arginine depletion in MAF reach a 
critical level, sufficient to disrupt normal NO production 
in these cells. IL-6, and IDO activity were detected, but 
none of them showed any significant difference between 
MAFs and DFs (Fig. 6c, d). No detectable amounts of 
TGF-β and PGE2 were found in either MAF- or DF-CMs 
(not shown), which is consistent with our findings (Sup-
plementary Fig. 1) that the presence or absence of MAF- 
or DF-CM did not modify the impact of external TGF-β 
on CTLs gzmB production. Interestingly, elevated levels 
of secreted CXCL12 were detected in MAF supernatants, 
which is in line with other reports that describe an elevated 
CXCL12 production by CAFs in both human and murine 
carcinomas [5, 27] (Fig. 6e).
MAF‑derived l‑arginase induces increased 
expression of TIGIT and BTLA in CD8+ T cells
To test whether increased l-arginase activity in MAFs was 
responsible for MAF-induced CD8+ T cell suppression, 
additional batches of MAF-CM and DF-CM were prepared 
both in the presence and absence of BEC hydrochloride, 
a potent and selective inhibitor of both l-arginase 1 and 
2. Next, all previously observed T cell-related functional 
aberrations were re-evaluated for stability with and with-
out l-arginase inhibition. These analyses disclosed that 
MAF-suppressed CD69 and gzmB expression, and MAF-
reduced CTL-mediated killing could not be restored by 
elimination of l-arginase activity in MAFs (Supplemen-
tary Fig. 2). However, the MAF-CM-elevated expression 
of BTLA and TIGIT could be neutralized by selective inhi-
bition of l-arginase (Fig. 7a). To corroborate these find-
ings, we transfected MAFs with a mammalian expression 
vector encoding the full-length human arginase 2 under 
the control of a CMV promoter (Supplementary Fig. 3), 
and examined its effect on both BTLA and TIGIT. We 
found that forced expression of arginase in MAFs further 
increased BTLA and TIGIT on CD8+ T cells (Fig. 7b). 
Taken together, these data indicate that MAF-mediated 
enhancement of BTLA and TIGIT expression on CD8+ T 
cells is an l-arginase-dependent phenomenon.
Fig. 5  MAF maintain increased expression of the immune checkpoint 
regulators HVEM and VISTA. Comparative analysis of cell surface 
Herpesvirus entry mediator (HVEM), Galectin-3, Galectin-9, Pro-
grammed death-ligand 1 (PD-L1), CD155 (poliovirus receptor) and 
V-domain Ig suppressor of T cell activation (VISTA) expression 
(mean fluorescence intensity) on MAF and DF cells, as analyzed by 
flow cytometry (n = 6 Mann–Whitney U test BTLA p = 0.029 and 
HVEM p = 0.0311). Data from three independent experiments
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Discussion
Research has shown that in the absence of T cell-activating 
immunotherapy, high counts of FAP + MAFs accumulate in 
the tumor stroma and this may serve as a negative prognostic 
marker [28]. This study provides multiple lines of evidence 
that soluble factors released by MAFs affect various aspects 
of cytotoxic T cell function. Our data suggest that ex vivo 
MAFs can create a milieu that influences virtually all phases 
of T cell activation ranging from early post-activation events 
to terminal differentiation and exertion of effector functions. 
Without exception, all observed effects are detrimental to 
CD8+ T cell activity. This raises the question whether MAFs 
in vivo were capable of contributing to the complex, multi-
pronged attack mounted by cancer cells on CTLs, leading 
to the well-documented dysfunctionality of TILs in various 
advanced solid tumors, including melanoma.
Here, we show that FAP + melanoma-associated fibro-
blasts display an immunosuppressive, arguably tumor pro-
moting phenotype, which is in line with observations of 
others made in colorectal [29] and pancreatic cancers [5]. 
MAF-derived soluble factors significantly downregulate 
the expression of CD69 on the surface of activated CD8+ T 
cells compared to healthy DFs, suggesting that fundamental 
perturbation of T cells occurs even at the earliest phases 
of T cell activation. MAF-derived factors reduce granzyme 
B production and release, but do not alter IFNγ produc-
tion, secretion, or cytotoxic degranulation of CD8+ T cells, 
implying that selective impairment of distinct components 
of the T cell effector machinery may occur in the vicinity of 
MAFs. In line with this finding, in redirected killing assays, 
we demonstrate that MAFs suppress ex vivo killing capacity 
of CD8+ T cells too, which may be related to the attenuated 
granzyme B production. It is important to note, however, 
that experimental killing assays [16], including the redi-
rected killing assays used here [17, 19, 30] measure ex vivo 
killing capacity, and shall be interpreted with caution, as 
their results may not necessarily reflect actual antitumor kill-
ing activity in vivo. Nevertheless, these findings suggest that 
MAFs may not only disturb the process of T cell activation, 
but also could undermine effective elimination of target cells 
(i.e., cancer cells) in the tumor parenchyma.
Fig. 6  Increased arginase activity and apparent NOS uncoupling 
in MAF cells. a Intracellular arginase activity of MAF and DF 
cells derived from the same patients were compared in cell lysates. 
Results shown were normalized to total protein content (min to 
max; p = 0.0186, n = 5, ratio paired t test) (data from two independ-
ent experiments). b MAF and DF cells from the same patients were 
stained with DAF-FM and the frequency of NO producing cells was 
assessed (min–max; p = 0.0113, n = 5, paired t test, data from two 
independent experiments). Significant difference was found in the 
amount of produced NO (MFI) per cell, too (p = 0.0021, data not 
shown). c, d Evaluation of IL-IDO activity/l-kynurenine production, 
IL-6 and CXCL12 release (paired t test, p = 0.0178, n = 8, one experi-
ment) in MAF and DF cells by ELISA
Fig. 7  Increased MAF arginase activity is responsible for aberrant 
ICR expression on CTLs. Comparative analysis of ICR expression 
on activated non-naïve/memory CTLs exposed to conditioned media 
collected from MAF maintained in the presence and absence of BEC 
hydrochloride, a selective arginase inhibitor, and transgenic arginase 
overexpression (CMV-Arg). BTLA (a) and TIGIT (b) expression of 
activated CD45RO+ CD8+ T cells is shown under the influence of 
BEC and CMV-Arg. (two-way RM ANOVA, *p < 0.05, **p < 0.01 
***p < 0.001, n = 8). Data from two independent experiments
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Moreover, we found selective dysregulation of distinct 
immune checkpoint regulators on CD8+ T cells by MAFs, as 
well. The ratios of TIGIT- and BTLA-positive CD8+ T cells 
were significantly elevated by soluble MAF factors, particu-
larly among non-naïve/memory CD45RO+ T cells. This 
observation is intriguing because several ICRs, including 
BTLA [20] and TIGIT [31] are potent negative regulators 
of T cell activity and are actively researched as promising 
targets for next generation immunotherapies. Monoclo-
nal antibodies targeting BTLA are subject of preclinical 
studies, while TIGIT blockade is in Phase I clinical trials 
(NCT03119428). Further, activity of CD45RO+ T cells is 
decisive in the rejection of various solid tumors [32–34], 
including checkpoint blockade therapy-induced remission 
of melanoma. Several lines of evidence indicate that fre-
quency of circulating CD45RO+ T cells [35], and particu-
larly therapy-induced systemic [36, 37] and intratumoral 
[38] expansion of the CD45RO+ subset are of major impor-
tance in the success of checkpoint blockade. Interestingly, 
changes observed in CD8+ T cell ICR expression (higher 
BTLA levels) were paralleled by complementary changes 
in MAF-derived ICR ligands (increased HVEM expres-
sion). The simultaneous up-regulation of HVEM and BTLA 
observed on MAFs and MAF-exposed CTLs, respectively, 
raises the question whether MAFs could further suppress 
CTLs by activating the HVEM-BTLA ICR signaling axis, 
should direct contact between the two cell types occur [39].
Related to the findings above, potential differences 
were searched between the MAF and DF cells that could 
shed light on the mechanisms responsible for the appar-
ent dysfunction of MAF-exposed CD8+ T cells. We found 
that intracellular signaling cascades of CD8+ T cells were 
affected by prolonged exposition to soluble MAF mediators. 
Increased ERK1/2 and decreased NF-κB phosphorylation 
suggest that MAF reprogram two essential T cell signal-
ing pathways, possibly the RAS guanyl-releasing protein 
1–ERK1/2 pathway, and the protein kinase Cθ–NF-κB 
pathway. Mature naïve T cells activated by aCD3 (stimu-
lation) and aCD28 (co-stimulation) rely on both pathways 
equally for TCR/CD3 signaling [40]. However, it has been 
extensively documented that sufficient CD28-induced co-
stimulation depends on the protein kinase Cθ–NF-kB path-
way [41-44]. As full T cell maturation and exertion of effec-
tor functions are both dependent on proper co-stimulation, 
these data indicate that the phenotypic changes observed in 
the effector functions of MAF-exposed CD8+ T cells may 
originate in weakened T cell co-stimulation.
Furthermore, we found that arginase activity was highly 
elevated in MAF cells, to an extent that it resulted in both 
uncoupling of NOS and clear disturbances of the steady-
state NO production. l-arginine depletion induces T cell 
suppression by (i) down-regulation of CD3ζ [45], (ii) G0/
G1 cell-cycle arrest due to failed upregulation of cyclin D3 
protein synthesis and cdk4 activation [46], (iii) increased 
phosphorylation of eIF2 and (iv) global suppression of 
protein synthesis in affected T cells [47] (v) interference 
with lytic function in situ [48]. So far, direct evidence for 
CAFs inducing T cell suppression via arginase has not been 
provided, although clinical data clearly show that ARG2 
overexpression by CAFs predisposes to poor overall sur-
vival in pancreatic cancer [24] and ARG2 production by 
CAF has been observed in unrelated solid tumors, too [49]. 
It has been proposed that cancer-associated fibroblasts may 
also exploit arginase to interfere with T cell activity [1, 2, 
50]; however, to our best knowledge, this is the first report 
substantiating this hypothesis on the example of melanoma-
associated fibroblasts.
We found that selective blockade of arginase activity by 
a potent, small molecular inhibitor, BEC hydrochloride, was 
able to neutralize the increased expression of TIGIT and 
BTLA on CD45RO+ CD8+ T cells 48 h after activation, 
while arginase transfection had the opposite effect. Collec-
tively, these data suggest that aberrant ICR expression on 
CTLs in the presence of MAF-CM is an arginase-mediated 
phenomenon. Interestingly, a recent paper also suggests that 
BTLA may depend on arginase, as in the absence of arginase 
2, BTLA mRNA expression decreases in activated CD8+ T 
cells 48 h upon activation [51]. Of note, BEC hydrochlo-
ride maintained its effectiveness even after MAF arginase 
expression was increased by stable transfection. This is 
interesting because arginase inhibitors, either alone or in 
combination with checkpoint inhibitors, are currently being 
tested as anti-neoplastic agents in various solid malignan-
cies (NCT02903914). These clinical trials are in concert 
with preclinical data suggesting that arginase blockade may 
increase efficiency of the PD-1/PD-L1 blockade [52, 53]. 
Thus, our data may support the notion that arginase inhi-
bition may be a tool that makes some solid tumors more 
vulnerable to multiple forms of ICR-blockade.
Last but not least, we demonstrated that MAFs secrete 
more CXCL12 as compared to autologous DF cells. High 
amounts of CXCL12 can act as a chemorepellent, and may 
be implicated in the exclusion of CD8+ T cells from solid 
tumors [5, 54]. Although multiple lines of evidence suggest 
that increased CXCL12 secretion by CAFs is pro-tumor-
ogenic [27], further research is needed to explore to exact 
role of MAF-derived CXCL12 in the biology of melanoma.
One particularly intriguing aspect of our observations 
is the remarkable robustness of the CTL-suppressive MAF 
phenotype. In all experiments, MAFs were maintained in the 
absence of melanoma cells for several weeks before being 
used for CD8+ T cell assays. Our data clearly demonstrate 
that in spite of extensive in vitro cultivation, MAFs did not 
revert to the rather harmless DF phenotype. The CTL-sup-
pressive MAF phenotype remained stable even after separa-
tion from the cancer microenvironment. This observation 
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supports the notion put forward recently by many leading 
authors of the field, that at least some changes promoting 
the transition of DF to CAF may rely on highly stable epige-
netic modifications [55–58]. That is, some parameters of the 
MAF phenotype may arise following a single priming event, 
resulting in long-term consequences, rather than being main-
tained by cancer cells via persistently secreted cytokines or 
similar mechanisms [1, 59]. Although the exact mecha-
nism of this tumor-initiated transformation of fibroblasts is 
unknown, some studies suggest that direct cell–cell contact, 
as well as cell-derived soluble factors such as TGF-beta and 
LIF may play [55, 60] an important role in the this process.
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